Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Organovo Holdings (NASDAQ:ONVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
67.0% of Arbutus Biopharma Corporation shares are held by institutional investors. Comparatively, 23.9% of Organovo Holdings shares are held by institutional investors. 10.0% of Arbutus Biopharma Corporation shares are held by insiders. Comparatively, 10.2% of Organovo Holdings shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Arbutus Biopharma Corporation and Organovo Holdings, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Arbutus Biopharma Corporation||0||0||5||0||3.00|
Arbutus Biopharma Corporation presently has a consensus target price of $15.00, suggesting a potential upside of 106.90%. Organovo Holdings has a consensus target price of $6.94, suggesting a potential upside of 344.71%. Given Organovo Holdings’ higher possible upside, analysts clearly believe Organovo Holdings is more favorable than Arbutus Biopharma Corporation.
Volatility & Risk
Arbutus Biopharma Corporation has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Organovo Holdings has a beta of 3.02, indicating that its share price is 202% more volatile than the S&P 500.
This table compares Arbutus Biopharma Corporation and Organovo Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Arbutus Biopharma Corporation||N/A||-28.97%||-21.71%|
Valuation & Earnings
This table compares Arbutus Biopharma Corporation and Organovo Holdings’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Arbutus Biopharma Corporation||$1.85 million||215.64||-$65.74 million||($5.13)||-1.41|
|Organovo Holdings||$4.33 million||38.23||-$38.77 million||($0.39)||-4.00|
Organovo Holdings has higher revenue and earnings than Arbutus Biopharma Corporation. Organovo Holdings is trading at a lower price-to-earnings ratio than Arbutus Biopharma Corporation, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Organovo Holdings Company Profile
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.